Amarin | AMRN - Cost Of Sales


Amarin reported $26.05M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amarin USD 26.05M 1.41M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Halozyme Therapeutics USD 102.15M 29.14M Dec/2025
Heron Therapeutics USD 11.12M 795K Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Novartis USD 3.54B 3M Dec/2025